Pepstatin A, an aspartic proteinase inhibitor, suppresses RANKL-induced osteoclast differentiation

Journal of Biochemistry

Volumn 139, Issue 3, 2006, Pages 583-590

  Yoshida, Hajime ^a   Okamoto, Kuniaki ^a   Iwamoto, Tsutomu ^a   Sakai, Eiko ^a   Kanaoka, Kazuhiro ^a   Hu, Jin Ping ^a   Shibata, Mitsue ^a   Hotokezaka, Hitoshi ^a   Nishishita, Kazuhisa ^a   Mizuno, Akio ^a   Kato, Yuzo ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Aspartic proteinase; Cathepsin; Osteoclast; Pepstatin A

Indexed keywords

ASPARTIC PROTEINASE; ASPARTIC PROTEINASE INHIBITOR; CATHEPSIN D; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PEPSTATIN; PROTEIN KINASE B; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MOUSE; NONHUMAN; OSTEOCLAST; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ANIMALS; ANIMALS, NEWBORN; ASPARTIC ENDOPEPTIDASES; CELL DIFFERENTIATION; MALE; MICE; OSTEOCLASTS; PEPSTATINS; PROTEASE INHIBITORS; RANK LIGAND;

ANIMALIA;

EID: 33646357266     PISSN: 0021924X     EISSN: None     Source Type: Journal    
DOI: 10.1093/jb/mvj066     Document Type: Article

References (44)

1. Lacey, D.L., Timms, E., Tan, H.L., Kelley, M.J., Dunstan, C.R., Burgess, T., Elliot, R., Colombero, A., Elliot, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y.X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J., and Boyle, W.J. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176
2. Fuller, K., Wong, B., Fox, S., Choi, Y., Chambers, T.J. (1998) TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J. Exp. Med. 188, 997-1001
3. Kong Y-Y., Yoshida, H., Sarosi, I., Tan H-L., Timms, E., Capparelli, C., Morrony, S., Oliver-dos-Santos, A.J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C.R., Lacey, D.L., Mak, T.W., Boyle, W.J., and Penninger, J.M. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323
4. Hsu, H., Lacey, D.L., Dunstan, C.R., Solovyev, I., Colombero, A., Timms, E., Tan, H.L., Elliott, G., Kelly, M.J., Sarosi, I., Wang, L., Xia, X.Z., Elliott, R., Chiu, L., Black, T., Scully, S., Capparelli, C., Morony, S., Shimamoto, G., Bass, M.B., Boyle, W.J. (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. 96, 3540-3545
5. Burgess, T.L., Qian, Y., Kaufman, S., Ring, B.D., Van, G., Capparelli, C., Kelly, M.J., Hsu, H., Boyle, W.J., Dunstan, C.R., Hu, S., Lacey, D.L. (1999) The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 145, 527-538
6. Jimi, E., Akiyama, S., Tsurukai, T., Okahashi, N., Kobayashi, K., Udagawa, N., Nishihara, T., Takahashi, N., Suda, T. (1999) Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J. Immunol. 163, 434-442
7. Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M.T., and Martin, T.J. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocrine reviews 20, 345-357
8. Boyle, W.J., Simoonet, W.S., and Lacey, D.L. (2003) Osteoclast differentiation and activation. Nature 423, 337-342
9. Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., Morinaga, T., Higashio, K. (1998) RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 253, 395-400
10. Dougall, W.C., Glaccum, M., Charrier, K., Rohrback, K., Brasel, K., Smedt, T. Daro, E., Smith, J., Tometsko, M.E., Maliszewski, C.R., Armstrong, A., Shen, V., Bain, S., Cosman, D., Anderson, D., Morrissey, P.J., Peschon, J.J., and Schuh, J. (1999) RANK is essential for osteoclast and lymph node development. Gene. Dev. 13, 2412-2424
11. Wong, B.R., Josien, R., Lee, S.Y., Vologodskaia, M., Steinman, R.M., Choi, Y. (1998) The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor. J. Biol. Chem. 273, 28355-28359
12. Galibert, L., Tometsko, M.E., Anderson, D.M., Cosman, D., Dougall, W.C. (1998) The involvement of multiple tumor necrosis factoir receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-κB, a member of the TNFR superfamily. J. Biol Chem. 273, 34120-34127
13. Zhang, Y.H., Heulsmann, A., Tondravi, M.M., Mukherjee, A., and Abu-Amer, Y. (2001) Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J. Biol. Chem. 276, 563-568
14. Ye, H., Arron, J.R., Lamothe, B., Cirilli, M., Kobayashi, T., Shevde, N.K., Segal, D., Dzivenu, O.K., Vologodskaia, M., Yim, M., Singh, S., Pike, J.W., Darnay, E.G., Choi, Y., and Wu, H. (2002) Distinct molecular mechanism for initiating TRAF6 signaling. Nature 418, 443-447
15. Armstrong, A.P., Tometsko, M.E., Glaccum, M., Sutherland, C.L., Cosman, D., and Dougall, W.C. (2002) A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J. Biol. Chem. 277, 44347-44356
16. Ha, H., Kwak, H.B., Lee, S.W., Jin, K.M., Kim, H.M., Kim, H.H., and Lee, Z.H. (2004) Reactive oxygen species mediate RANK signaling in osteoclasts. Exp. Cell Res. 301, 119-127
17. Gohda, J., Akiyama, T., Koga, T., Takayanagi, H., Tanaka, S., and Inoue, J. (2005) RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J. 24, 790-799
18. Matsumoto, M., Sudo, T., Saito, T., Osada, H., and Tsujimoto, M. (2000) Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-κB ligand (RANKL). J. Biol. Chem. 275, 31155-31161
19. Lee, S.E., Woo, K.M., Kim, S.Y., Kim, H.M., Kwack, K., Lee, Z.H., Kim, H.H. (2002) The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 30, 71-77
20. Li, X., Udagawa, N., Itho, K., Suda, K., Murase, Y., Nishihara, T., Suda, T., Takahashi, N. (2002) p38 MAP-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 143, 3105-3113
21. Matsumoto, M., Kogawa, M., Wada, S., Yakayanagi, H., Tsujimoto, M., Katayama, S., Hisatake, K., and Nogi, Y. (2004) Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.l. J. Biol. Chem. 279, 45969-45979
22. 2+ accelerates nuclear translocation of nuclear factor κB in osteoclast. J. Biol Chem. 278, 8286-8293
23. Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., et al. (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889-901
24. Ishida, N., Hayashi, K., Hoshijima, M., Ogawa, T., Koga, S., Miyatake, Y., et al. (2002) Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J. Biol. Chem. 277, 41147-41156
25. Franzoso, G., Carlson, L., Xing, L., Poljak, L., Shores, E.W., Brown, K.D., Leonardi, A., Tran, T., Boyce, B.F., and Siebenlist, U. (1997) Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 11, 3482-3496
26. Grigoriadis, A.E., Wang, Z.-Q., Cecchini, M.G., Hofstetter, W., Felix, R., Fleisch, H.A., and Wagner, E.F. (1994) c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266, 443-448
27. Simonet, W., Lacey, D., Dunstan, C., Kelly, M., Chang, M.S., Luthy, R., Nguyen, H., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H.L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T., Hill, D., Pattison, W., Campbell, P., Sander, S., Van, G., Tarpley, J., Derby, P. Lee, R., AmgenEST program, and Boyle, W. (1997) Osteo-protegerin: A novel secreted protein involved in the regulation of bone density. Cell 89, 309-319
28. Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., Kanno, T., Murakami, A., Tsuda, E., Morinaga, T., and Higasio, K. (1998) Identity of osteoclastgenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastgenesis in Vitro. Endocrinology 139, 1329-1337
29. Collin-Osdoby, P., Rothe, L., Anderson, F., Nelson, M., Maloney, W., and Osdoby, P. (2001) Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J. Biol. Chem. 276, 20659-20672
30. Goto, T., Kiyoshima, T., Moroi, R., Tsukuba, T., Nishimura, Y., Himeno, M., Yamamoto, K., and Tanaka, T. (1994) Localization of cathepsins B, D, and L in the rat osteoclast by immuno-light and -electron microscopy. Histochemistry 101, 33-40
31. Goto, T., Tsukuba, T., Ayasaka, N., Yamamoto, K., and Tanaka, T. (1992) Immunocytochemical localization of cathepsin D in the rat osteoclast. Histochemistry 97, 13-18
32. Saftig, P., Hunziker, E., Wehmeyer, O., Jones, S., Boyde, A., Rommerskirch, W., et al. (1998) Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin K-deficient mice. Proc. Natl. Acad. Sci. USA 95, 13453-13458.
33. Gowen, M., Lazner, F., Foffs, R., Kapadia, R., Field, J., Tavaria, M., et al. (1999) Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 14, 1654-1663
34. Gelb, G.D., Shi, G.P., Chapman, H.A., and Desnick, R.J. (1996) Pycnodysostosis, a disease caused by cathepsin K deficiency. Science 273, 1236-1238
35. Brage, M., Lie, A., Ransjo, M., Kasprzykowski, F., Kasprzykowska, R., Abrahamson, M., Grubb, A., Lerner, U.F. (2004) Osteoclastogenesis in decreased by cycteine proteinase inhibitors. Bone 34, 412-424
36. Yoshimine, Y., Tsukuba, T., Isobe, R., Sumi, M., Akamine, A., Maeeda, K., and Yamamoto, K. (1995) Specific immunocyto-chemical localization of cathepsin E at the ruffled border membrane of active osteoclasts. Cell Tissue Res. 281, 85-91
37. Suzawa, T., Miyaura, C., Inada, M., Maruyama, T., Sugimoto, Y., Ushikubi, F., Ichikawa, A., Narumiya, S., and Suda, T. (2000) The role of prostaglandin E receptor subtypes (EP1, EP2, EP3 and EP4) in bone resorption: An analysis using specific agonists for the respective EPs. Endocrinology 141, 1554-1559
38. Iwamoto, T., Fukumoto, S., Kanaoka, K., Sakai, E., Shibata, M., Fukumoto, E., Inokuchi, J., Takamiya, K., Furukawa, K., Furukawa, K., Kato, Y., and Mizuno, A. (2001) Lactosylceramide is essential for the osteoclastogenesis mediated by macrophage-colony-stimulating factor and receptor activator of nuclear factor-κB ligand. J. Biol. Chem. 276, 46031-46038
39. Yamamoto, K. and Marchesi, V.T. (1984) Purification and characterization of acid proteinase from human erythrocyte membranes. Biochem. Biophys. Acta 790, 208-218
40. Khapli, S.M., Mangashetti, L.S., Yogesha, S.D., and Wani, M.R. (2003) IL-3 act directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-κB ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage 1. J. Immunol. 171, 142-151
41. Takayanagi, H. (2005) Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med. 83, 170-179
42. Chen C-S., Chen W-N., Zhou, M., Arttamangkul, S., and Haugland, R.P. (2000) Probing the cathepsin D using a BODIPY FL-pepstatin A: applications in fluorescence polarization and microscopy. J. Biochem. Biophys. Methods 42, 137-151
43. Annunziata, C.M., Safiran, Y.J., Irving, S.G., Kasid, U.N, and Cossman, J. (2000) Hodgkin disease: pharmacologic intervention of the CD40-NFκB pathway by a protease inhibitor. Blood 96, 2841-2848
44. Hauer, J., Püscher, S., Ramakrishnan, P., Simon, U., Bongers, M., Federle, C., and Engehnann, H. (2005) TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-κB pathway by TRAF-binding TNFRs. Proc. Natl. Acad. Sci. USA 102, 2874-2879